15182-94-2

Basic information

• Product Name: 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE
• Synonyms: 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE
• CAS NO: 15182-94-2
• Molecular Formula: C₁₃H₁₉NO₂
• Molecular Weight: 221.29546
• Mol File: 15182-94-2.mol

Chemical Properties

• Boiling Point: 340.1°C at 760 mmHg
• Flash Point: 159.5°C
• Appearance: /
• Density: 1.029g/cm³
• Vapor Pressure: 8.81E-05mmHg at 25°C
• Refractive Index: 1.531
• PKA: 9.50±0.25(Predicted)
• CAS DataBase Reference: 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE(15182-94-2)
• EPA Substance Registry System: 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE(15182-94-2)

Safety Data

• Hazardous Substances Data: 15182-94-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE is used as a reagent in organic synthesis for the preparation of various other compounds. Its unique structure allows for versatile reactions and the formation of a wide range of products.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE is used as a starting material for the development of new pharmaceutical products. Its antimicrobial and anti-inflammatory properties make it a promising candidate for the treatment of various diseases and conditions.
Used as a Fluorescent Probe in Biochemical Research:
4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE is used as a fluorescent probe in biochemical and medical research. Its ability to emit fluorescence upon interaction with specific molecules or cellular components makes it a valuable tool for studying cell signaling, receptor mechanisms, and other biological processes.
Used in Antimicrobial Applications:
Due to its antimicrobial properties, 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE is used in the development of antimicrobial agents. It can be incorporated into pharmaceutical formulations or applied in other industries, such as food preservation, to inhibit the growth of harmful microorganisms.
Used in Anti-inflammatory Applications:
4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE is also used in the development of anti-inflammatory agents. Its ability to reduce inflammation can be beneficial in the treatment of various inflammatory conditions and diseases.

InChI:InChI=1/C13H19NO2/c1-3-14(4-2)9-10-16-13-7-5-12(11-15)6-8-13/h5-8,11H,3-4,9-10H2,1-2H3

Upstream product

• 869-24-9 2-chloro-N,N-diethylethylamine hydrochloride 
• 123-08-0 4-hydroxy-benzaldehyde 
• 100-52-7 benzaldehyde 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 
• 109-89-7 diethylamine 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 
• 54373-15-8 4-(2-chloroethoxy)benzaldehyde 
• 100-35-6 2-(diethylamino)ethyl chloride 

Downstream Products

• 115145-51-2 diethyl-[2-(4-inden-1-ylidenemethyl-phenoxy)-ethyl]-amine 
• 47367-87-3 {2-[4-(6-chloro-benzothiazol-2-yl)-phenoxy]-ethyl}-diethyl-amine 
• 97018-38-7 {2-[4-(6-ethoxy-benzothiazol-2-yl)-phenoxy]-ethyl}-diethyl-amine 
• 26628-05-7 C₂₅H₄₄N₂O 
• 101632-41-1 {2-[4-(2-diethylamino-ethoxy)-phenyl]-benzothiazol-6-yl}-dimethyl-amine 
• 34329-20-9 C₁₄H₂₂N₄O₂ 
• 46926-19-6 4-(2-Diethylaminoethoxy)-zimtsaeurenitril 
• 38528-90-4 [2-(4-benzothiazol-2-yl-phenoxy)-ethyl]-diethyl-amine 
• 31230-87-2 {2-[4-(2,3-dihydro-benzothiazol-2-yl)-phenoxy]-ethyl}-diethyl-amine 
• 53756-00-6 2-[4-(2-diethylamino-ethoxy)-benzyl]-11-trifluoromethyl-7H-benzo[2,3][1,4]oxazepino[6,5,4-ij]quinolin-3-one 
• 56484-88-9 2-[4-(2-diethylamino-ethoxy)-benzylidene]-11-trifluoromethyl-1,2-dihydro-7H-benzo[2,3][1,4]oxazepino[6,5,4-ij]quinolin-3-one 
• 3704-49-2 2-(4-Chlor-phenyl)-1-<4-(2-diethylamino-ethoxy)-phenyl>-ethanol 
• 34329-35-6 3-(2-Diaethylaminoaethoxy)benzaldoxim 
• 88137-03-5 (E)-3-[4-(2-Diethylamino-ethoxy)-phenyl]-2-thiophen-2-yl-acrylonitrile; hydrochloride 

Relevant articles and documents

Design, synthesis, antitrypanosomal activity, DNA/RNA binding and in vitro ADME profiling of novel imidazoline-substituted 2-arylbenzimidazoles

Novel imidazoline benzimidazole derivatives containing diversely substituted phenoxy moieties were synthesized with the aim of evaluating their antitrypanosomal activity, DNA/RNA binding affinity and in vitro ADME properties. The presence of the diethylaminoethyl subunit in 18a–18c led to enhanced antitrypanosomal potency, particularly for 18a and 18c, which contain unsubstituted and methoxy-substituted phenoxy moieties. They were found to be > 2-fold more potent against African trypanosomes than nifurtimox. Fluorescence and CD spectroscopy, thermal denaturation assays and computational analysis indicated a preference of 18a–18c toward AT-rich DNA and their minor groove binding mode. Replacement of the amidine group with less basic and ionisable nitrogen-containing moieties failed to improve membrane permeability of the investigated compounds. Due to structural diversification, the compounds displayed a range of physico-chemical features resulting in variable in vitro ADME properties, leaving space for further optimization of the biological profiles.

Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease

A series of novel chalcone-O-alkylamine derivatives were designed, synthesized and evaluated as multifunctional anti-Alzheimer's disease agents. Based on the experimental results, compound 23c exhibited good inhibitory potency on both acetylcholinesterase

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers

A series of quinazoline derivatives with benzylidene hydrazine carboxamide were designed and synthesised as EGFR inhibitors. Most compounds exhibited exceptional anti-proliferative activity against A549, HepG2, MCF-7 and H1975 cells. Furthermore, six compounds demonstrated excellent inhibition activity against EGFRWT with the IC50 value both less than 2 nM. Among the six compounds, 44 exhibited the strongest activity (0.4 nM) and potently inhibited EGFRL858R/T790M (0.1 μM). Excitingly, the most potent compound 14 showed excellent enzyme inhibitory activity with 6.3 nM and 8.4 nM for both EGFRWT and EGFRT790M/L858R. The result of AO single staining and Annexin V/PI staining showed that the compound 14 and 44 could induce remarkable apoptosis of A549 cells. The compound 14 arrested the cell cycle at the S phase and compound 44 arrested the cell cycle at the G0 phase in A549 cells. These preliminary results demonstrate that compound 14 and 44 may be promising lead compound-targeting EGFR.

USE OF DISUBSTITUTED BENZENES TO CONTROL INSECTICIDE-RESISTANT PESTS

The invention is in the technical field of insect control and relates to the use of a disubstituted benzenes for controlling insecticide-resistant pests such as mosquitoes and cockroaches.

Ionic liquids for efficient hydrogen sulfide and thiol scavenging

Functionalised pyridinium and ammonium ionic liquids bearing a Michael acceptor are shown to scavenge H2S gas and various thiols, in most cases, without the aid of any added bases. Utilising the effective non-volatility of ionic liquids and 'ta

Novel 8-(p-substituted-phenyl/benzyl)xanthines with selectivity for the A2A adenosine receptor possess bronchospasmolytic activity

A new series of 8-(p-substituted-phenyl/benzyl)xanthines has been synthesized and evaluated in vitro for adenosine receptor binding affinity and in vivo for bronchospasmolytic effects. It was observed that the nature of substituent at para-position of 8-phenyl/benzyl group on the xanthine scaffold remarkably affects the binding affinity and selectivity of xanthine derivatives for various adenosine receptor subtypes and also their bronchospasmolytic effects. Newly synthesized 8-phenylxanthines displayed potent binding affinity and significant selectivity for A2A receptors and also produced potent bronchospasmolytic effects. Replacement of phenyl ring with benzyl moiety at C8 of xanthine skeleton resulted in notable reduction in adenosine receptor affinity and broncholytic effects.

Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII

4-Sulfamoyl-N-(3-morpholinopropyl)benzamide (I-1), N-(3-morpholinopropyl)benzene-1,4-disulfonamide (I-2) and N-(4-diethylaminoethoxybenzyl)benzene-1,4-bis(sulfonamide (I-3), were prepared and assayed as inhibitors of four carbonic anhydrase (CA) isoenzyme

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The invention provides compounds of Formula (I) : wherein R1 is hydrogen, OH, halo, -CN, -NO2, -N=0, -NHOQ2, -OQ2, -SOQ2, -SO2Q2, -SON(Q2)2, - SO2N(Q2)2, -N(Q2)2, -C(O)OQ2, -C(O)Q2, -C(O)N(Q2)2, -C(=NQ2)NQ2, -NQ2C(=NQ2)NQ2, - C(O)N(Q2)(OQ2), -N(Q2)C(O)-Q2, -N(Q2)C(O)N(Q2)2, -N(Q2)C(O)O-Q2, -N(Q2)SO2Q2, -N(Q2)SOQ2, aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, or heteroaryl ring, each aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, and heteroaryl ring optionally including 1-3 substituents independently selected Q3; R2 and R3 are each independently hydrogen, OH, oxo, aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, optionally substituted with 1-3 of Q1 or Q2; X is a branched or straight C1-12 aliphatic chain wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, -CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, - O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, -SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-; G and G1 are each independently a branched or straight C1-2 aliphatic chain, or heterocycloalkyl, wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, - CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, -O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, - SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-, and pharmaceutically acceptable salts, solvates or prodaigs thereof, as well as methods of treating estrogen receptor mediated diseases and disorders using the compounds of Formula (I).

Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3

The inhibition of FLT-3 activity is an interesting target for the treatment of acute myeloid leukemia (AML). The serendipitous identification of FLT-3 inhibitors from a CK1/γ-secretase programme provided compounds with dual inhibitory activity. We analyzed the structure-activity relationship of these inhibitors and derivatized them to arrive at compounds with reduced impact on γ-secretase activity and enhanced FLT-3 inhibition.

Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators

In an systematic attempt to develop novel Selective Estrogen Receptor Modulators (SERMs), chiral 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2- hydroxynaphthalen-1-yl)methyl)piperidin-4-ols were designed based on an accepted pharmacophore model. Simpler prototypes, viz. racemic 1-((2-hydroxynaphthalen- 1-yl)arylmethyl)piperidin-4-ols, were first synthesized to develop kinetic resolution to pure enantiomers. Simultaneously, a series of racemic 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl)methyl) piperidin-4-ols were evaluated against estrogen-responsive human MCF-7 breast cancer cells, but the compounds were found to be moderately active. The lack of potency could be due to the molecular bulk resulting in inadequate fit at the receptor. Subsequently, the molecular motif was modified to achiral 1-(4-(2-(dialkylamino)ethoxy)benzyl)naphthalen-2-ols by removing the piperidinol moiety. Bioevaluation of this new series of compounds displayed significantly enhanced cytotoxicity against MCF-7 cells. A representative compound for this series showed estrogen receptor alpha binding activity and the action is that of an antagonist.